The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
The product is expected to start contributing meaningfully to the revenue from FY25
The inspection was a cGMP Inspection and had ended with NIL observations
The Leaders of G20 met in New Delhi and committed to strengthening global health and implementing one health approach
The generous donation includes multiple medical equipments
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Subscribe To Our Newsletter & Stay Updated
